Last 48 quarters of trend data · Healthcare · Medical - Healthcare Information Services
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
National Research Corporation's quarterly P/E stands at 30.3x, up 136.9% year-over-year — indicating the stock has re-rated higher or earnings have softened. EV/EBITDA has expanded 64.3% YoY to 14.5x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 37.56 | 30.32 | 56.95 | 17.75 | — | 12.80 | 15.75 | 23.81 | 22.07 | 36.68 | 27.47 | 34.66 | 37.51 |
| — | +136.9% | +261.6% | -25.5% | — | -65.1% | -42.7% | -31.3% | -41.2% | -5.6% | -20.5% | +15.0% | +29.3% | |
| P/S Ratio | 3.20 | 2.67 | 2.91 | 2.09 | 2.80 | 2.19 | 2.79 | 3.79 | 3.92 | 6.72 | 6.39 | 7.22 | 7.43 |
| — | +22.0% | +4.1% | -45.0% | -28.6% | -67.4% | -56.3% | -47.5% | -47.3% | -8.9% | +5.5% | +10.1% | +14.9% | |
| P/B Ratio | 31.26 | 27.57 | 29.26 | 20.17 | 17.85 | 9.91 | 13.18 | 15.68 | 13.65 | 25.69 | 19.84 | 18.93 | 13.83 |
| — | +178.2% | +122.1% | +28.6% | +30.7% | -61.4% | -33.6% | -17.2% | -1.3% | +78.2% | +54.6% | +29.7% | -1.6% | |
| P/FCF | 27.96 | 17.40 | 16.89 | 7.09 | — | 20.09 | 53.25 | 17.34 | 90.45 | 30.04 | 30.58 | 51.23 | 59.81 |
| — | -13.4% | -68.3% | -59.1% | — | -33.1% | +74.1% | -66.2% | +51.2% | -49.2% | -18.7% | +25.7% | +110.1% | |
| EV / EBITDA | 17.05 | 14.46 | 17.77 | 9.23 | 34.26 | 8.80 | 10.63 | 15.56 | 14.23 | 24.24 | 19.10 | 24.24 | 24.64 |
| — | +64.3% | +67.1% | -40.7% | +140.8% | -63.7% | -44.3% | -35.8% | -42.3% | -6.0% | +12.8% | +22.2% | +31.7% | |
| EV / EBIT | 22.80 | 20.09 | 26.10 | 11.85 | 70.73 | 10.34 | 12.30 | 18.53 | 16.65 | 28.12 | 21.39 | 27.35 | 27.83 |
| — | +94.2% | +112.3% | -36.0% | +324.7% | -63.2% | -42.5% | -32.3% | -40.2% | -3.1% | -9.5% | +23.7% | +32.5% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
National Research Corporation's operating margin was 16.0% in Q1 2026, up 2.7 pp QoQ and down 9.6 pp YoY. The trailing four-quarter average of 14.1% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin contracted 3.4% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 56.3% | 54.6% | 54.3% | 57.8% | 56.8% | 56.5% | 61.1% | 57.3% | 61.7% | 60.8% | 63.7% | 61.4% | 63.2% |
| — | -3.4% | -11.1% | +1.0% | -8.0% | -7.0% | -4.1% | -6.8% | -2.4% | -0.1% | +0.6% | -0.0% | +0.1% | |
| Operating Margin | 16.4% | 16.0% | 13.3% | 22.4% | 4.7% | 25.6% | 26.0% | 22.3% | 25.3% | 24.8% | 30.8% | 26.2% | 25.9% |
| — | -37.5% | -48.9% | +0.4% | -81.6% | +3.3% | -15.7% | -15.1% | -2.3% | +0.4% | -4.0% | -11.0% | -16.0% | |
| Net Margin | 8.4% | 9.3% | 5.1% | 11.9% | -0.3% | 17.2% | 17.8% | 15.9% | 17.6% | 18.0% | 23.3% | 20.8% | 20.1% |
| — | -46.3% | -71.3% | -25.0% | -101.8% | -4.2% | -23.7% | -23.5% | -12.3% | -5.7% | +33.9% | -5.7% | -9.9% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 51.2% | 23.4% | 12.7% | 23.1% | -0.4% | 19.0% | 19.9% | 15.2% | 16.0% | 14.8% | 16.6% | 11.6% | 9.5% |
| — | +23.5% | -36.2% | +52.1% | -102.6% | +28.2% | +20.0% | +30.9% | +67.7% | +55.9% | +74.6% | -4.5% | -13.9% | |
| ROA | 8.7% | 2.4% | 1.3% | 3.0% | -0.1% | 4.3% | 5.0% | 4.5% | 5.1% | 5.2% | 7.3% | 6.2% | 5.4% |
| — | -44.7% | -73.2% | -34.4% | -101.5% | -17.3% | -32.0% | -27.0% | -5.2% | -0.7% | +46.0% | +1.5% | -5.6% | |
| ROIC | 18.8% | 4.7% | 3.9% | 6.1% | 1.3% | 7.0% | 8.2% | 7.2% | 8.3% | 8.3% | 11.0% | 9.8% | 9.5% |
| — | -33.0% | -52.6% | -14.5% | -84.9% | -15.0% | -25.8% | -26.4% | -12.5% | -13.1% | -20.3% | -28.2% | -33.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
National Research Corporation's Debt/EBITDA ratio is 10.1x, down from 11.6x last quarter — elevated, raising questions about debt serviceability. Debt/Equity has risen for 8 consecutive quarters, indicating increasing financial leverage that investors should watch closely.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 5.65 | 5.78 | 5.65 | 5.59 | 3.80 | 2.20 | 2.06 | 1.55 | 1.05 | 1.14 | 0.81 | 0.41 | 0.26 |
| — | +163.1% | +174.4% | +261.0% | +261.4% | +93.0% | +154.8% | +276.2% | +309.1% | +303.4% | +148.9% | +19.9% | -27.9% | |
| Debt / EBITDA | 2.62 | 10.08 | 11.60 | 8.06 | 24.31 | 6.43 | 5.80 | 5.63 | 4.07 | 4.12 | 3.01 | 2.07 | 1.83 |
| — | +56.8% | +100.0% | +43.1% | +497.6% | +56.0% | +92.7% | +171.9% | +121.8% | +103.6% | +75.3% | +10.4% | -4.0% | |
| Current Ratio | 0.55 | 0.52 | 0.55 | 0.53 | 0.70 | 0.54 | 0.55 | 0.47 | 0.37 | 0.41 | 0.67 | 0.61 | 1.21 |
| — | -3.8% | +1.0% | +13.2% | +90.1% | +31.8% | -18.8% | -22.9% | -69.5% | -67.2% | -48.6% | -49.3% | -7.1% | |
| Quick Ratio | 0.55 | 0.52 | 0.55 | 0.53 | 0.70 | 0.54 | 0.55 | 0.47 | 0.37 | 0.41 | 0.67 | 0.61 | 1.21 |
| — | -3.8% | +1.0% | +13.2% | +90.1% | +31.8% | -18.8% | -22.9% | -69.5% | -67.2% | -48.6% | -49.3% | -7.1% | |
| Interest Coverage | 4.75 | 4.44 | 3.39 | 5.29 | 1.56 | 9.59 | 13.17 | 11.33 | 15.97 | 14.54 | 43.79 | 63.74 | 50.19 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Total return calculator · dividends reinvested
Calculate ReturnsDollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Compare NowQuick answers to the most common questions about buying NRC stock.
National Research Corporation's current P/E is 37.6x. The average P/E over the last 3 quarters is 35.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
National Research Corporation's current operating margin is 16.4%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking National Research Corporation's business trajectory between earnings reports.